Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

[1]  Matthias Eiber,et al.  68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging , 2018, The Journal of Nuclear Medicine.

[2]  M. Schwaiger,et al.  Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. , 2018, European urology.

[3]  T. Holland-Letz,et al.  Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  M. burge,et al.  Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. , 2018, Clinical nuclear medicine.

[5]  N. Lenzo,et al.  Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer , 2018, Diagnostics.

[6]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Shiozawa,et al.  Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy , 2017, Journal of cellular biochemistry.

[8]  T. Schlomm,et al.  Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients , 2016, Scientific Reports.

[9]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[10]  Younghun Jung,et al.  Growth Arrest‐Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow , 2016, Journal of cellular biochemistry.

[11]  Younghun Jung,et al.  Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow , 2016, Scientific Reports.

[12]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[13]  S. Aedo,et al.  Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells , 2016, BJU international.

[14]  James E. Verdone,et al.  Technical challenges in the isolation and analysis of circulating tumor cells , 2016, Oncotarget.

[15]  K. Pienta,et al.  The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer , 2016, Oncotarget.

[16]  K. Tabata,et al.  Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer , 2016, International journal of molecular sciences.

[17]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[18]  P. Carmeliet,et al.  Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow , 2016, Oncotarget.

[19]  Yupei Zhao,et al.  Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. , 2016, Medical hypotheses.

[20]  C. Bieberich,et al.  Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. , 2016, Cancer research.

[21]  N. Murray,et al.  Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[22]  S. Sleijfer,et al.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. , 2015, European urology.

[23]  J. Sabourin,et al.  Circulating tumor cell isolation: the assets of filtration methods with polycarbonate track-etched filters. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[24]  R. Dueñas,et al.  Consideraciones clínicas de la expresión de P504S y metaloproteinasa de matriz 2 en células prostáticas circulantes en sangre diseminadas como resultado de una biopsia prostática trans-rectal guiada por ecografía. , 2015 .

[25]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[26]  D. Kong,et al.  Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes , 2015, The Prostate.

[27]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[28]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[29]  Klaus Pantel,et al.  Biology, detection, and clinical implications of circulating tumor cells , 2014, EMBO molecular medicine.

[30]  C. Sander,et al.  Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling , 2014, Molecular Cancer Therapeutics.

[31]  F. Buttgereit,et al.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone , 2014, Clinical & Experimental Metastasis.

[32]  F. Buttgereit,et al.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone , 2014, Clinical & Experimental Metastasis.

[33]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[34]  N. Weigel,et al.  Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. , 2014, The international journal of biochemistry & cell biology.

[35]  M. Koch,et al.  Prognostic relevance of minimal residual disease in colorectal cancer. , 2014, World journal of gastroenterology.

[36]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[37]  A. Tewari,et al.  Inflammation and prostate cancer: the role of interleukin 6 (IL‐6) , 2014, BJU international.

[38]  V. Weinberg,et al.  Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration‐resistant prostate cancer , 2014, International journal of cancer.

[39]  K. Polyak,et al.  Oncogene-like induction of cellular invasion from centrosome amplification , 2014, Nature.

[40]  Gary An,et al.  Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model , 2014, Theoretical Biology and Medical Modelling.

[41]  A. Voigt,et al.  Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. , 2014, Cancer research.

[42]  Xuelei Ma,et al.  Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis , 2014, Tumor Biology.

[43]  M. Terris,et al.  Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database , 2014, Prostate Cancer and Prostatic Disease.

[44]  M. Nieto.  Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.

[45]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[46]  A. N. Meyer,et al.  Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells , 2013, PloS one.

[47]  T. Fehm,et al.  Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients , 2013, Proceedings of the National Academy of Sciences.

[48]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[49]  I. Thompson,et al.  Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer , 2013, The Prostate.

[50]  D. Hayes,et al.  Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer , 2013, Molecular oncology.

[51]  K. Pienta,et al.  GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation , 2013, PloS one.

[52]  N. Murray,et al.  Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications , 2013, Journal of oncology.

[53]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[54]  N. Murray,et al.  Secondary Circulating Prostate Cells Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease , 2013, TheScientificWorldJournal.

[55]  C. Scheiermann,et al.  Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. , 2013, Annual review of immunology.

[56]  E. Antonarakis,et al.  Tumorigenic potential of circulating prostate tumor cells , 2013, Oncotarget.

[57]  M. King,et al.  Computational and Experimental Models of Cancer Cell Response to Fluid Shear Stress , 2013, Front. Oncol..

[58]  N. Murray,et al.  Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study , 2012, Bone marrow research.

[59]  Sridhar Ramaswamy,et al.  Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. , 2012, Cancer discovery.

[60]  N. Murray,et al.  Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. , 2012, International journal of molecular medicine.

[61]  S. Nilsson,et al.  Bone, microenvironment and hematopoiesis , 2012, Current opinion in hematology.

[62]  K. Pantel,et al.  Circulating epithelial cells in patients with benign colon diseases. , 2012, Clinical chemistry.

[63]  Y. Castier,et al.  Minimal residual disease in solid neoplasia: New frontier or red-herring? , 2012, Cancer treatment reviews.

[64]  Alan Wells,et al.  Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases , 2012, Cancer Microenvironment.

[65]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Rammensee,et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. , 2012, Cancer research.

[67]  Li Li,et al.  Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. , 2012, Cancer research.

[68]  Lei Ding,et al.  Endothelial and perivascular cells maintain haematopoietic stem cells , 2011, Nature.

[69]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[70]  M. Ignatiadis,et al.  Minimal residual disease and circulating tumor cells in breast cancer , 2011, Breast Cancer Research.

[71]  B. Trock,et al.  Can we stop prostate specific antigen testing 10 years after radical prostatectomy? , 2011, The Journal of urology.

[72]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[73]  Andrew J Armstrong,et al.  Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011 .

[74]  N. Murray,et al.  Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol , 2011, Indian journal of urology : IJU : journal of the Urological Society of India.

[75]  Lei Cui,et al.  Connective tissue growth factor enhances the migration of gastric cancer through downregulation of E‐cadherin via the NF‐κB pathway , 2011, Cancer science.

[76]  Ben D. MacArthur,et al.  Mesenchymal and haematopoietic stem cells form a unique bone marrow niche , 2010, Nature.

[77]  Alan Wells,et al.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition , 2010, Molecular Cancer.

[78]  D. Lowy,et al.  E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases , 2010, Oncogene.

[79]  Klaus Pantel,et al.  Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. , 2010, European journal of cancer.

[80]  B. Trock,et al.  290 CAN WE STOP PSA TESTING 10 YEARS AFTER RADICAL PROSTATECTOMY , 2010 .

[81]  M. Srougi,et al.  E-cadherin and β-catenin Loss of Expression Related to Bone Metastasis in Prostate Cancer , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[82]  R. Dueñas,et al.  Expresión del supresor tumoral CD82 en células prostáticas primarias y secundarias en la circulación sanguínea (CPCs) de pacientes con cáncer prostático , 2010 .

[83]  W. Park,et al.  Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high‐risk prostate cancer , 2010, Journal of surgical oncology.

[84]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[85]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[86]  E. Crooke,et al.  Laminin‐1 induces E‐cadherin expression in 3‐dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  I. Holen,et al.  Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples , 2009, Clinical & Experimental Metastasis.

[88]  C. Vicentini,et al.  Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels. , 2009, Urology.

[89]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[90]  M. Koutsilieris,et al.  Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance , 2009, Molecular medicine.

[91]  G. Calaf,et al.  Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients. , 2009, Oncology reports.

[92]  R. Raychowdhury,et al.  Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.

[93]  Peter Friedl,et al.  Proteolytic interstitial cell migration: a five-step process , 2009, Cancer and Metastasis Reviews.

[94]  W. Ellis,et al.  Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence , 2009, Clinical Cancer Research.

[95]  J. Köllermann,et al.  Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  K. Pienta,et al.  Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer , 2008, Journal of cellular biochemistry.

[97]  George Poste,et al.  The "seed and soil" hypothesis revisited. , 2008, The Lancet. Oncology.

[98]  A. Wells,et al.  E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas , 2008, Clinical & Experimental Metastasis.

[99]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[100]  R. Babaian,et al.  Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. , 2008, The Journal of urology.

[101]  P. Baumann,et al.  ANTI-ADHESION evolves to a promising therapeutic concept in oncology. , 2008, Current medicinal chemistry.

[102]  K. Pienta,et al.  The evolving biology and treatment of prostate cancer. , 2007, The Journal of clinical investigation.

[103]  Y. De rycke,et al.  A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients , 2007, International journal of cancer.

[104]  S. Fosså,et al.  Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy , 2007, International journal of cancer.

[105]  D. Ribatti,et al.  Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination , 2006, Clinical and Experimental Medicine.

[106]  R. Crevoisier,et al.  High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[107]  K. Miura,et al.  Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression , 2006, Nature Medicine.

[108]  J. Gala,et al.  Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study , 2006, British Journal of Cancer.

[109]  E. Sacco,et al.  Clinical and Pathological Characteristics of Patients Presenting with Biochemical Progression after Radical Retropubic Prostatectomy for Pathologically Organ-Confined Prostate Cancer , 2006, Urologia Internationalis.

[110]  A. Haese*,et al.  Anatomic radical retropubic prostatectomy—long-term recurrence-free survival rates for localized prostate cancer , 2006, World Journal of Urology.

[111]  J. Behrens,et al.  E-cadherin modulates Wnt-dependent transcription in colorectal cancer cells but does not alter Wnt-independent gene expression in fibroblasts. , 2006, Experimental cell research.

[112]  Lynette M. Smith,et al.  Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. , 2005, Urologic oncology.

[113]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[114]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[115]  K. Pienta,et al.  Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. , 2005, Neoplasia.

[116]  D. Peeper,et al.  Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB , 2004, Nature.

[117]  A. Partin,et al.  An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. , 2004, The Journal of urology.

[118]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[119]  A. Partin,et al.  Biochemical failure after radical prostatectomy in men with pathologic organ‐confined disease: pT2a versus pT2b , 2004, Cancer.

[120]  S. Hirohashi,et al.  5-Aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis , 2004, Clinical & Experimental Metastasis.

[121]  I. Weissman,et al.  Circulation and Chemotaxis of Fetal Hematopoietic Stem Cells , 2004, PLoS biology.

[122]  Dominique Trudel,et al.  An immunohistochemical study , 2013 .

[123]  M. Rubin,et al.  E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.

[124]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[125]  B. Tombal,et al.  Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy , 2003, The Prostate.

[126]  D. Russo,et al.  Different phenotypes of colon carcinoma cells interacting with endothelial cells: role of E-selectin and ultrastructural data , 2003, Cell and Tissue Research.

[127]  J. Moul,et al.  Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.

[128]  C. Sheehan,et al.  Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer , 2003, Modern Pathology.

[129]  W. Ellis,et al.  Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. , 2003, Urology.

[130]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[131]  D. Farkas,et al.  Optical Imaging of PKH‐Labeled Hematopoietic Cells in Recipient Bone Marrow In Vivo , 2002, Stem cells.

[132]  D. McDonald,et al.  Significance of blood vessel leakiness in cancer. , 2002, Cancer research.

[133]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[134]  John Trachtenberg,et al.  A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. , 2002, The Journal of urology.

[135]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[136]  E. Winn-Deen,et al.  Decreased expression of catenins (α and β), p120 CTN, and E‐cadherin cell adhesion proteins and E‐cadherin gene promoter methylation in prostatic adenocarcinomas , 2001 .

[137]  S. Parodi,et al.  Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer , 2000, Journal of cellular biochemistry.

[138]  J. Herman,et al.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  X. Zhang,et al.  Hematopoietic progenitor cells grow on 3T3 fibroblast monolayers that overexpress growth arrest-specific gene-6 (GAS6). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[140]  E. Bergstralh,et al.  Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. , 2000, The Journal of urology.

[141]  P. Albers,et al.  Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR. , 2000, Anticancer Research.

[142]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[143]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[144]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[145]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[146]  F. Wawroschek,et al.  Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy? , 1999, Urological Research.

[147]  I. Mazo,et al.  Adhesion and homing of blood‐borne cells in bone marrow microvessels , 1999, Journal of leukocyte biology.

[148]  J. Köllermann,et al.  Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer , 1999, International journal of cancer.

[149]  P. Quesenberry,et al.  Stem cell homing: rolling, crawling, and nesting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[150]  K. Luzzi,et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.

[151]  P. Carroll,et al.  Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant , 1998, Cancer.

[152]  M. Banerjee,et al.  Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  G. Mundy,et al.  Mechanisms of bone metastasis , 1997, Cancer.

[154]  K. Pantel,et al.  Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  R. Bresalier,et al.  Liver endothelial E‐selectin mediates carcinoma cell adhesion and promotes liver metastasis , 1997, International journal of cancer.

[156]  J. Köllermann,et al.  Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation , 1997, International journal of cancer.

[157]  O. Cussenot,et al.  Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. , 1997, European journal of cancer.

[158]  W. Ellis,et al.  Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[159]  D. Bostwick,et al.  Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. , 1996, The Journal of urology.

[160]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[161]  S. Loric,et al.  Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy , 1995, The Lancet.

[162]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[163]  J. Köllermann,et al.  Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. , 1995, European journal of cancer.

[164]  M. Melamed,et al.  Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma , 1994, The Prostate.

[165]  S. Humphreys,et al.  Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[166]  W. Isaacs,et al.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. , 1992, Cancer research.

[167]  L. Liotta,et al.  The significance of hematogenous tumor cell clumps in the metastatic process. , 1976, Cancer research.

[168]  I. Fidler,et al.  Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine , 1970 .

[169]  B. Fleshler,et al.  Physiology of the Gastrointestinal Tract , 1969 .

[170]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[171]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[172]  F. Jakob,et al.  A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. , 2018, Cancer research.

[173]  S. Aedo,et al.  Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome , 2018, Asian Pacific journal of cancer prevention : APJCP.

[174]  P. Carmeliet,et al.  Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow , 2016, Oncotarget.

[175]  N. Murray,et al.  Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[176]  N. Murray,et al.  [Expression of P504S and matrix metalloproteinase-2 in circulating prostate cells disseminated as a result of transrectal ultrasound guided biopsy as determined by immunocytochemistry: Clinical implications]. , 2015, Archivos españoles de urología.

[177]  N. Murray,et al.  Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[178]  J. Schneider,et al.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. , 2011, Bone.

[179]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[180]  M. Toi.  Long-term outcomes of aromatase inhibition for breast cancer. , 2008, The Lancet. Oncology.

[181]  J. Huot,et al.  Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis , 2007, Clinical & Experimental Metastasis.

[182]  S. Fosså,et al.  The prognostic impact of cytokeratin‐positive cells in bone marrow of patients with localized prostate cancer , 2003, International journal of cancer.

[183]  E. Winn-Deen,et al.  Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. , 2001, Cancer.

[184]  J. Holland,et al.  Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. , 1996, The Journal of urology.

[185]  J. Izbicki,et al.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.